Mitsubishi Tanabe Pharma, a leading Japanese pharmaceuticals company, has turned to the UiPath Business Automation Platform to improve business operational efficiency that would not have been possible with only human labor.
Mitsubishi Tanabe Pharma aims to create hope for anyone facing an illness. The industry continues to face challenges in developing valuable drugs that truly meet the needs of patients, which makes new drug development more difficult year by year.
By introducing UiPath, Mitsubishi Tanabe Pharma says it is promoting digital technology reform in its new drug development and overall business productivity.
Mitsubishi Tanabe Pharma assumed the RPA Center of Excellence, which consolidates all administrative tasks, including pharmaceutical information, accounting, general affairs and HR for companies under the entire Group into a single point of contact.
From the beginning, in anticipation of an era of no-code/low-code development that does not use programming languages, the introduction of the system proceeded on a “self-driven” basis, where on-site employees are encouraged to identify and automate target tasks on their own.
Rob Enslin, Co-Chief Executive Officer, UiPath, said: “We are pleased to play a key role in Mitsubishi Tanabe Pharma Group’s automation journey, by helping them achieve operational efficiency and improve their digital capabilities. By augmenting their automation program with citizen development, Mitsubishi Tanabe Pharma can future-proof its business and build a hybrid human-digital workforce of the future.”
